Rigel Pharmaceuticals (RIGL) Change in Acquisitions & Divestments (2010 - 2026)

Rigel Pharmaceuticals has reported Change in Acquisitions & Divestments for 17 years, with the latest figure at $15.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 43.65% year-over-year to $15.9 million; the trailing twelve-month figure through Mar 2026 stood at $66.0 million (up 55.05% YoY), and the FY2025 full-year result was $61.1 million, up 53.98% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $15.9 million, up from $13.5 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $29.8 million in Q1 2022, with the low at $6.0 million in Q4 2023.
• Average Change in Acquisitions & Divestments over 5 years is $15.3 million, with a median of $15.6 million recorded in 2023.
• Year-over-year, Change in Acquisitions & Divestments surged 2002.72% in 2022 and slumped 71.95% in 2023.
• Tracing RIGL's Change in Acquisitions & Divestments over 5 years: stood at $21.2 million in 2022, then slumped by 71.65% to $6.0 million in 2023, then gained by 12.5% to $6.8 million in 2024, then jumped by 100.73% to $13.5 million in 2025, then climbed by 17.68% to $15.9 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $15.9 million (Q1 2026), $13.5 million (Q4 2025), and $20.7 million (Q3 2025), per Business Quant data.

Peer Comparison